FR2903006A1 - Cosmetic process for care and/or make-up to improve the brilliance of the complexion of a dark skin, comprises application of a composition comprising a C-glycoside derivative in a medium on - Google Patents

Abstract

Cosmetic process of care and/or make-up to improve the brilliance of the complexion of a dark skin, comprises application of a composition comprising a C-glycoside derivative (I) in a medium on the skin.

Description

The present invention relates to the use of at least one derivative

  C-glycoside as an agent for improving the radiance of the complexion of the skin and particularly that of dark skin More specifically, it relates to a cosmetic and / or makeup care method intended to improve the radiance of the skin by the application on a dark skin, especially of photoype IV to VI, of a composition comprising at least one C-glycoside derivative. The skin is constantly subjected to environmental factors that in particular cause cutaneous changes in texture, color, transparency and leads to a dull complexion, without radiance. These various environmental factors include UV rays, dehydration, pollution, stress, lack of sleep, cigarettes, alcohol, diet, etc. They generate dark skin changes in the skin. dermis, epidermis or vascular system.

  Among the modifications that take place in response to environmental stress, we observe in particular: the appearance of inter and intramolecular bypasses linked to glycation and glycation phenomena described in the literature as being involved in the yellowing of collagen fibers and more generally of yellowing of tissues; a deregulation of the desquamation process leading to a heterogeneity of the cutaneous surface; loss of hydration of the skin and / or an alteration of the vascular system which leads to a decrease in oxygenation, which causes, on the one hand, malfunctions of the cell metabolism and, on the other hand, an alteration of the skin color that appears less pink, without brilliance. The set of alterations observed in the various tissues of the skin leads more generally to a decrease in skin regeneration, an alteration of the color, of the transparency and the appearance of a dull complexion.

  These physiological changes seem to translate macroscopically for dark skin including an ashy appearance of the skin, a less luminous complexion, less transparent, and / or less homogeneous.  Thus, there remains a need for a cosmetic or dermatological composition making it possible to mitigate these skin manifestations, and in particular able to provide a brighter, transparent, uniform, homogeneous, and / or natural-looking complexion.  The present invention results more particularly from the discovery by the inventors that C-glycoside derivatives prove to be precisely advantageous for meeting this need.  In general, sugars and sugar derivatives are products already used for various purposes for the formulation of cosmetic compositions intended both for the care of the skin and for the care and / or washing of keratinous fibers.  Thus, in WO 99/24009, D-xylose and its derivatives are proposed for the purpose of preparing cosmetic or pharmaceutical products intended to improve the functionality of the cells of the epidermis.  Among the sugars which can be used in the field, the C-glycoside derivatives are particularly interesting.  Thus, certain C-glycoside derivatives have demonstrated interesting biological properties, in particular to fight against the aging of the epidermis and / or against the drying of the skin.  Such compounds are described in particular in WO 02/051828.  These compounds are more particularly represented by the formula: ## STR2 ## in which S represents a monosaccharide or a polysaccharide, R represents different linear or cyclic radicals and the group X can represent a group chosen from: -CO-, -CH (NR1R2) - , CHR'-, -C (= CHR ') - with RI, R2 and R' may represent different radicals, including the hydroxyl radical for RI and R2.  Thus, the present invention relates, in one of its aspects, to the use of at least one C-glycoside derivative as an agent for improving the radiance of the complexion of a skin, especially a dark skin, and in particular of a skin of phototype IV to VI of the FITZPATRICK classification.  According to another of its aspects, the invention relates to a method of cosmetic and / or makeup care, in particular intended to improve the radiance of the complexion of a skin and particularly of a dark skin comprising the application on said skin of A composition comprising in a physiologically acceptable medium at least one C-glycoside derivative.  In particular, a dark skin targeted by the invention belongs to phototypes IV to VI of the FITZPATRICK classification.  For the purposes of the present invention, the term "dark skin", especially skin whose average brightness L * measured on the forehead, cheekbones and chin in the CIE 1976 color space, is less than 55.  The saturation C * may be for example between 10 and 30, especially between 12 and 28.  The hue angle values h can be, for example, from about 38 to about 54.  The values of clarity 10 L * can be less than or equal to 50, or even 45 or 40 for the darkest skins, while being able to remain, for most skins, greater than 30.  These skins can still be classified on the basis of their reactivity to the effects of solar radiation according to the scale proposed by FITZPATRICK.  According to this scale, the different existing skins can be distinguished according to the following phototypes: Type Reactivity of the skin Origin I Burns always, never bronze Celtic II Burns always, little bronze Germanic III Burns moderately, progressively bronze European IV Burns slightly, bronze very easily Mediterranean, Indian, Asian V Burns rarely, intensely bronze Middle East - South American VI Never burns, strongly pigmented African The dark skin which is more particularly the subject of the present invention belong to phototypes IV to VI.  More particularly representative of phototypes IV, V and VI, populations of ethnic origin such as for example African, North African, Indian and African American.  More particularly, a composition according to the invention makes it possible to improve the radiance of the complexion and in particular to increase the luminosity and the transparency of the dark skin while at the same time making the color of the face more homogeneous, in order, for example, to to homogenize the complexion without unduly degrading the natural aspect of the skin.  In particular, it can advantageously allow, after application to the skin, to provide a negative variation of Aicox coxelography index of less than or equal to -0.4, preferably less than or equal to -0.5, and even lower or equal to -1, for a skin having before the application of said composition an index of coxellography icox greater than or equal to 5.  By stainless steel coxellography index, the product of the standard deviations 6a * X 6b * X 6L * is designated for all the zones observed, as will be specified hereinafter.  DETERMINATION OF THE COXELLOGRAPHIC INDEX icox The measurement of the radiance of the complexion is carried out using a chromasphere.  This is an acquisition device comprising a sphere inside which are arranged several white light sources, not apparent, so that the light gaining its opening is as homogeneous as possible.  The face of the person whose color is to be measured is placed in this opening and images are acquired using color cameras or digital cameras.  Prior to the acquisition of the images, the acquisition chain is calibrated by placing reference colorimetric standards in the field of cameras, for example according to the method described in US Pat. No. 6,362,849, the content of which is incorporated in FIG. this request by reference.  Such a device is described in particular in the patent application FR 2 829 344.  By means of a colorimetric calibration method, the chromasphere makes it possible to make color measurements in the CIE Lab color space.  Thus, each pixel of the image corresponds to a color in the CIE Lab space.  The analysis of the dispersion of these colors in a region of interest of the image gives information on the color homogeneity of the zone.  This is called the coxellography index ie0x.  Calculation of the coxellographic index i ~ oX 2903006 The standard deviation a for each parameter L *, a * and b * can be calculated before and after treatment with the composition according to the invention.  The stainless steel coxellography index is defined as the product of the three standard deviations 6a *, 6b * and 6L *: icox ù 6a * X 6b * X 6L *.  The more homogeneous the skin color, the lower the coxellography index icox.  As specified above, a composition according to the invention makes it possible to obtain a negative variation of Aicox coxellography index less than or equal to -0.4, preferably less than or equal to -0.5, more preferably less than or equal to 1, for a skin having before the application of said composition an index of coxellography icox greater than or equal to 5.  C-GLYCOSIDE DERIVATIVES A C-glycoside derivative that is suitable for use in the invention may be a compound of the following general formula (I): embedded image in which: R represents: a linear alkyl radical, saturated with C 1 to C 20, in particular C 1 to C 10, or unsaturated C 2 to C 20, especially C 2 to C 10, or a branched or cyclic alkyl radical, saturated or unsaturated, C 3 to C 20, in particular C 3 to C 10; a linear hydrofluoro- or perfluoroalkyl radical, linear saturated C1 to C20, in particular C1 to C10, or unsaturated C2 to C20, in particular C2 to C10, or branched or cyclic, saturated or unsaturated, C3 to C20 especially C3 to Clo; the hydrocarbon chain constituting said radicals may, if appropriate, be interrupted by 1, 2, 3 or more heteroatoms chosen from: oxygen, sulfur, nitrogen, and a silicon, and which may be optionally substituted with at least one radical chosen from: -OR4, -SR4, -NR4R5, -COOR4, -CONHR4, -CN-, a halogen atom, a hydrofluoro- or perfluoroalkyl radical, C1 to C6, and / or - a C3 to C8 cycloalkyl radical, with R4 and R5 being able to represent, independently of one another, a hydrogen atom, or an alkyl, perfluoroalkyl or linear hydrofluoroalkyl radical, saturated C1 to C30, especially C1 to Cu, or unsaturated C2 to C30, especially C2 to C12, or branched or cyclic, saturated or unsaturated, C3 to C30, especially C3 to C12; or a C6 to C10 aryl radical, X represents a radical chosen from the groups: where R1, R2 and R3 represent, independently of one another, a hydrogen atom, or an R radical, with R as defined above, and R '1 represents a hydrogen atom, a group OH or a radical R as defined above, RI may also denote a C6 to C10 aryl radical; S represents a monosaccharide; or a polysaccharide comprising up to 20 sugar units, in particular up to 6 sugar units, in pyranose and / or furanose and L and / or D series form, said mono- or polysaccharide being able to be substituted by a group hydroxyl necessarily obligatory, and optionally one or more function (s) amine (s) optionally protected (s), and - the bond S-CH2-X represents a bond of C-anomeric nature, which can be a or f3, so that their cosmetically acceptable salts, their solvates such as the hydrates es and their isomers.  In the context of the present invention, halogen means chlorine, fluorine, bromine or iodine.  The term aryl refers to an aromatic ring such as phenyl, optionally substituted with one or more C1-C4 alkyl radicals.  The term C3-C8 cycloalkyl means an aliphatic ring having 3 to 8 carbon atoms, including for example cyclopropyl, cyclopentyl and cyclohexyl.  Among the alkyl groups suitable for carrying out the invention, there may be mentioned in particular methyl, ethyl, isopropyl, n-propyl, n-butyl, t-butyl, isobutyl, sec-butyl, pentyl, n-butyl, hexyl, cyclopropyl, cyclopentyl, cyclohexyl, and allyl.  According to one embodiment of the invention, it is possible to use a C-glycoside derivative corresponding to formula (I) for which S can represent a monosaccharide or a polysaccharide containing up to 6 sugar units, in pyranose and / or furanose form. And L and / or D series, said mono- or polysaccharide having at least one hydroxyl function necessarily free and / or optionally one or more amine functions compulsorily protected, X and R otherwise retaining all the definitions previously given.  Advantageously, a monosaccharide of the invention may be selected from D-glucose, D-galactose, D-mannose, D-xylose, D-lyxose, L-fucose, L-arabinose, L -rhamnose, D-glucuronic acid, D-galacturonic acid, D-iduronic acid, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine and desirably D-glucose , D-xylose, N-acetyl-D-glucosamine or L-fucose, and in particular D-xylose.  More particularly, a polysaccharide of the invention containing up to 6 sugar units may be selected from D-maltose, D-lactose, D-cellobiose, D-maltotriose, a disaccharide associating a uronic acid selected from D-iduronic acid or D-glucuronic acid with a hexosamine selected from D-galactosamine, D-glucosamine, N-acetyl-D-galactosamine, N-acetyl-D-glucosamine, an oligosaccharide containing at least a xylose which may be advantageously chosen from xylobiose, methyl- (3-xylobioside, xylotriose, xylotetraose, xylopentaose and xylohexaose, and in particular xylobiose which is composed of two xylose molecules linked by a 1-4 bond; .  More particularly, S may represent a monosaccharide chosen from D-glucose, D-xylose, L-fucose, D-galactose, D-maltose and especially D-xylose.  According to another embodiment of the invention, it is possible to use C-glycoside derivatives corresponding to formula (I) for which X represents a group chosen from -CO-, -CH (OH) -, -CH (NR1R2 ) -, -CH (R) -, in particular -CO-, -CH (OH) -, -CH (NH2) -, -CH (NHCH2CH2CH2OH) -, -CH (NHPh) -, -CH (CH3) -, and more particularly a group.  ûCO-, -CH (OH) -, -CH (NH 2) -, and preferably a group -CH (OH) -, S and R also retaining all the definitions previously given.  According to another embodiment of the invention, it is possible to use a C-glycoside derivative corresponding to formula (I) for which R represents a linear, saturated C 1 to C 20, in particular C 1 to C 10, alkyl radical, or unsaturated C2 to C20, in particular C2 to C10, or a branched or cyclic C3 to C20 saturated or unsaturated alkyl radical; in particular at C3 to C10, and optionally substituted as previously described, S and R also retaining all the definitions previously given.  Preferably, R denotes a linear radical C1-C4, especially C1-C3, optionally substituted with -OH, -COOH or -COOR "2, R" 2 being a saturated alkyl radical C1-C4, especially ethyl.  Preferentially, R denotes an unsubstituted linear C1-C4, especially C1-C2, alkyl radical, in particular ethyl.  Among the C-glycoside derivatives of formula (I), use is preferably made of those for which: R represents a linear, saturated C 1 to C 20, in particular C 1 to C 10, or unsaturated C 2 to C 20 alkyl radical; in particular C 2 to C 10, or a branched or cyclic, saturated or unsaturated C 3 to C 20 alkyl radical; in particular C3 to C10, and optionally substituted as described above; S represents a monosaccharide as previously described; X represents -CO-, -CH (OH) -, -CH (NR1R2) -, -CH (R) - as previously described.  Preferably, a C-glycoside derivative of formula (I) is used, for which: R denotes a linear C1-C4 radical, in particular C1-C3, optionally substituted with OH, -COOH or -COOR "2, R" 2; being a saturated C1-C4 alkyl radical, especially ethyl; S represents a monosaccharide as previously described; X represents a group selected from CO-, -CH (OH) -, -C (NH2) -, -CH (NHCH2CH2CH2OH) -, -CH (NHPh) -, -CH (CH3) -, and more particularly a grouping CO-, -CH (OH) -, -CH (NH 2) -, and preferably a group -CH (OH) - Preferably, a C-glycoside derivative of formula (I) is used for which: - R denotes an alkyl radical linear unsubstituted C1-C4, especially C1-C2, in particular ethyl; S represents a monosaccharide as previously described; especially D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, and in particular D-xylose; X represents a group chosen from CO-, -CH (OH) -, -CH (NH 2) -, and preferentially a group -CH (OH) -.  Salts acceptable for non-therapeutic use of the compounds described in the present invention include conventional non-toxic salts of said compounds such as those formed from organic or inorganic acids.  By way of example, mention may be made of the salts of mineral acids, such as sulfuric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid and boric acid.  Mention may also be made of organic acid salts, which may comprise one or more carboxylic acid, sulphonic acid or phosphonic acid groups.  It may be linear, branched or cyclic aliphatic acids or aromatic acids.  These acids may furthermore comprise one or more heteroatoms chosen from O and N, for example in the form of hydroxyl groups.  These include propionic acid, acetic acid, terephthalic acid, citric acid and tartaric acid.  When the compound of formula (I) has an acidic group, the neutralization of the acidic group (s) may be carried out by a mineral base, such as LiOH, NaOH, KOH, Ca (OH) 2, NH 4 OH, Mg (OH) 2 or Zn (OH) 2; or with an organic base such as a primary, secondary or tertiary alkylamine, for example triethylamine or butylamine.  This primary, secondary or tertiary alkylamine may comprise one or more nitrogen atoms and / or oxygen and may therefore comprise, for example, one or more alcohol functions; mention may especially be made of 2-amino-methyl-2-propanol, triethanolamine, dimethylamino-2-propanol and 2-amino-2- (hydroxymethyl) -1,3-propanediol.  Mention may also be made of lysine or 3- (dimethylamino) propylamine.  Acceptable solvates for the compounds described in the present invention include conventional solvates such as those formed in the last step of preparing said compounds due to the presence of solvents.  By way of example, mention may be made of solvates due to the presence of water or of linear or branched alcohols, such as ethanol or isopropanol.  Among the C-glycoside derivatives of formula (I) used according to the invention, the following are particularly considered:  C- (3-D-xylopyranoside-n-propan-2-one; 2.  C-α-D-xylopyranoside-n-propan-2-one; 3.  1- [2- (3-Hydroxypropylamino) propyl] -C- (3-D-xylopyranose);  1- [2- (3-hydroxypropylamino) propyl] -C-u-D-xylopyranose; 5.  C- (3-D-xylopyranoside-2-hydroxypropane; 6.  C-u-D-xylopyranoside-2-hydroxypropane; 7.  C-13-D-xylopyranoside-2-aminopropane; 2903006 11 8.  C-α-D-xylopyranoside-2-aminopropane; 9.  C-13-D-xylopyranoside-2-phenylamino propane; 10.  C-α-D-xylopyranoside-2-phenylamino propane; 11.  3-methyl-4- (C- (3-D-xylopyranoside) -butyric acid ethyl ester;  3-methyl-4- (C-α-D-xylopyranoside) -butyric acid ethyl ester; 13.  6- (C- (3-D-xylopyranoside) -5-keto hexanoic acid;  6- (C-α-D-xylopyranoside) -5-keto hexanoic acid; 15.  6- (C-13-D-xylopyranoside) -5-hydroxy-hexanoic acid; 16.  6- (C-α-D-xylopyranoside) -5-hydroxy-hexanoic acid; 10 17.  6- (C- (3-D-xylopyranoside) -5-aminohexanoic acid;  6- (C-α-D-xylopyranoside) -5-aminohexanoic acid; 19.  6- (C- (3-D-xylopyranoside) -5-phenylamino-hexanoic acid;  6- (C-α-D-xylopyranoside) -5-phenylaminohexanoic acid; 21.  1- (C-P-D-xylopyranoside) -hexane-2,6-diol; 15 22.  1- (C-α-D-xylopyranoside) -hexane-2,6-diol; 23.  5- (C- (3-D-xylopyranoside) -4-keto-pentanoic acid;  5- (C-α-D-xylopyranoside) -4-keto-pentanoic acid; 25.  5- (C- (3-D-xylopyranoside) -4-hydroxy-pentanoic acid;  5- (C-α-D-xylopyranoside) -4-hydroxy-pentanoic acid; 20 27.  5- (C-13-D-xylopyranoside) -4-amino-pentanoic acid; 28.  5- (C-α-D-xylopyranoside) -4-amino-pentanoic acid; 29.  5- (C- (3-D-xylopyranoside) -4-phenylaminopentanoic acid;  5- (C-α-D-xylopyranoside) -4-phenylaminopentanoic acid; 31.  1- (C- (3-D-xylopyranoside) -pentane-2,5-diol; 32.  1- (C-α-D-xylopyranoside) -pentane-2,5-diol; 33.  1- (C- (3-D-fucopyranoside) propan-2-one;  1- (C-α-D-fucopyranoside) -propan-2-one; 35.  1- (C-13-L-fucopyranoside) -propan-2-one; 36.  1- (C-α-L-fucopyranoside) -propan-2-one; 30 37.  1- (C-13-D-fucopyranoside) -2-hydroxypropane; 2903006 12 38.  1- (C-α-D-fucopyranoside) -2-hydroxypropane; 39.  1- (C- (3-L-fucopyranoside) -2-hydroxypropane; 40.  1- (C-α-L-fucopyranoside) -2-hydroxypropane; 41.  1- (C-D-fucopyranoside) -2-amino-propane; 5 42.  1- (C-α-D-fucopyranoside) -2-amino-propane; 43.  1- (C- (3-L-fucopyranoside) -2-amino-propane;  1- (C-α-L-fucopyranoside) -2-amino-propane; 45.  1- (C- (3-D-fucopyranoside) -2-phenylaminopropane;  1- (C-α-D-fucopyranoside) -2-phenylamino propane; 10 47.  1- (C- (3-L-fucopyranoside) -2-phenylamino propane; 48.  1- (C-α-L-fucopyranoside) -2-phenylamino propane; 49.  3-methyl-4- (C- (3-D-fucopyranoside) -butyric acid ethyl ester;  3-methyl-4- (C-α-D-fucopyranoside) -butyric acid ethyl ester; 51.  3-methyl-4- (C- (3-L-fucopyranoside) -butyric acid ethyl ester;  3-methyl-4- (C-α-L-fucopyranoside) -butyric acid ethyl ester; 53.  6- (C- (3-D-fucopyranoside) -5-keto hexanoic acid;  6- (C-α-D-fucopyranoside) -5-keto hexanoic acid; 55.  6- (C-13-L-fucopyranoside) -5-keto hexanoic acid; 56.  6- (C-α-L-fucopyranoside) -5-keto hexanoic acid; 20 57.  6- (C- (3-D-fucopyranoside) -5-hydroxy-hexanoic acid;  6- (C-α-D-fucopyranoside) -5-hydroxy-hexanoic acid; 59.  6- (C-β-L-fucopyranoside) -5-hydroxy-hexanoic acid; 60.  6- (C-α-L-fucopyranoside) -5-hydroxy-hexanoic acid; 61.  6- (C- (3-D-fucopyranoside) -5-aminohexanoic acid;  6- (C-α-D-fucopyranoside) -5-aminohexanoic acid; 63.  6- (C-O-L-fucopyranoside) -5-aminohexanoic acid; 64.  6- (C-α-L-fucopyranoside) -5-aminohexanoic acid; 65.  1- (C-β-D-fucopyranoside) -hexane-2,6-diol; 66.  1- (C-α-D-fucopyranoside) -hexane-2,6-diol; 30 67.  1- (C- (3-L-fucopyranoside) -hexane-2,6-diol; 2903006 13 68.  1- (C-α-L-fucopyranoside) -hexane-2,6-diol; 69.  5- (C- (3-D-fucopyranoside) -4-keto-pentanoic acid; 70.  5- (C-α-D-fucopyranoside) -4-keto-pentanoic acid; 71.  5- (C- (3-L-fucopyranoside) -hexane-2,6-diol) -4-keto-pentanoic acid; 5 72.  5- (C-α-L-fucopyranoside) -hexane-2,6-diol) -4-keto-pentanoic acid; 73.  5- (C-13-D-fucopyranoside) -4-hydroxy-pentanoic acid; 74.  5- (C-α-D-fucopyranoside) -4-hydroxy-pentanoic acid; 75.  5- (C- (3-L-fucopyranoside) -4-hydroxy-pentanoic acid; 76.  5- (C-α-L-fucopyranoside) -4-hydroxy-pentanoic acid; 10 77.  5- (C- (3-D-fucopyranoside) -4-amino-pentanoic acid; 78.  5- (C-α-D-fucopyranoside) -4-amino-pentanoic acid 79.  5- (C- (3-L-fucopyranoside) -4-amino-pentanoic acid;  5- (C-α-L-fucopyranoside) -4-amino-pentanoic acid; 81.  1- (C-D-fucopyranoside) -pentane-2,5-diol; 15 82.  1- (C-α-D-fucopyranoside) -pentane-2,5-diol; 83.  1- (C- (3-L-fucopyranoside) -pentane-2,5-diol;  1- (C-α-L-fucopyranoside) -pentane-2,5-diol; 85.  1- (C- (3-D-glucopyranosyl) -2-hydroxypropane; 86.  1- (C-α-D-glucopyranosyl) -2-hydroxypropane; 87.  1- (C- (3-D-glucopyranosyl) -2-amino-propane; 88.  1- (C-α-D-glucopyrano-syl) -2-amino-propane; 89.  1- (C-β-D -glucopyrano-syl) -2-phenylamino-propane; 90.  1- (C-α-D-glucopyranosyl) -2-phenylamino propane; 91.  3-methyl-4- (C-3-D-glucopyranosyl) -butyric acid ethyl ester; 25 92.  3-methyl-4- (C-α-D-glucopyranosyl) -butyric acid ethyl ester; 93.  6- (C- (3-D-glucopyranosyl) -5-keto hexanoic acid;  6- (C-α-D-glucopyranosyl) -5-keto hexanoic acid; 95.  6- (C-β-D-glucopyranosyl) -5-hydroxy-hexanoic acid; 96.  6- (C-α-D-glucopyranosyl) -5-hydroxy-hexanoic acid; 30 97.  6- (C- (3-D-glucopyranosyl) -5-aminohexanoic acid;  6- (C-α-D-glucopyranosyl) -5-aminohexanoic acid; 99.  6- (C- (3-D-glucopyranosyl) -5-phenylamino-hexanoic acid;  6- (C-α-D-glucopyranosyl) -5-phenylamino-hexanoic acid; 101.  1- (C- (3-D-glucopyranosyl) hexane-2,6-diol;  1- (C-α-D-glucopyranosyl) hexane-2,6-diol; 103.  6- (C-13-D-glucopyranosyl) -5-keto-pentanoic acid; 104.  6- (C-α-D-glucopyranosyl) -5-keto-pentanoic acid; 105.  6- (C- (3-D-glucopyranosyl) -5-hydroxy-pentanoic acid;  6- (C-α-D-glucopyranosyl) -5-hydroxy-pentanoic acid; 10 107.  6- (C-β-D-glucopyranosyl) -5-amino-pentanoic acid; 108.  6- (C-α-D-glucopyranosyl) -5-hydroxy-pentanoic acid; 109.  6- (C-β-D-glucopyranosyl) -5-phenylaminopentanoic acid; 110.  6- (C-α-D-glucopyranosyl) -5-phenylaminopentanoic acid; 111.  1- (C- (3-D-glucopyranosyl) -pentane-2,5-diol;  1- (C-α-D-glucopyranosyl) -pentane-2,5-diol; 113.  1- (C- (3-D-galactopyranosyl) -2-hydroxypropane;  1- (C-α-D-galactopyranosyl) -2-hydroxypropane; 115.  1- (C 1-6 -D-galactopyranosyl) -2-amino-propane; 116.  1- (C-α-D-galactopyrano-syl) -2-amino-propane; 20 117.  1- (C-D-galactopyranosyl) -2-phenylamino propane; 118.  1- (C-α-D-galactopyranosyl) -2-phenylaminopropane; 119.  3-methyl-4- (β-D-galactopyranosyl) -butyric acid ethyl ester; 120.  3-methyl-4- (α-D-galactopyranosyl) -butyric acid ethyl ester; 121.  6- (C-13-D-galactopyranosyl) -5-keto hexanoic acid; 25 122.  6- (C-α-D-galactopyranosyl) -5-keto hexanoic acid; 123.  6- (C- (3-D-galactopyranosyl) -5-hydroxy-hexanoic acid;  6- (C-α-D-galactopyranosyl) -5-hydroxy-hexanoic acid; 125.  6- (C- (3-D-galactopyranosyl) -5-aminohexanoic acid;  6- (C-α-D-galactopyranosyl) -5-aminohexanoic acid; 30 127.  6- (C- (3-D-galactopyranosyl) 5-phenylamino-hexanoic acid;  6- (C-α-D-galactopyranosyl) 5-phenylaminohexanoic acid; 129.  1- (C- (3-D-galactopyranosyl) hexane-2,6-diol;  1- (C-α-D-galactopyranosyl) -hexane-2,6-diol; 131.  6- (C-β-D-galactopyranosyl) -5-keto-pentanoic acid; 5 132.  6- (C-α-D-galactopyranosyl) -5-keto-pentanoic acid; 133.  6- (C-β-D-galactopyranosyl) -5-hydroxy-pentanoic acid; 134.  6- (C-α-D-galactopyranosyl) -5-hydroxy-pentanoic acid; 135.  6- (C- (3-D-galactopyranosyl) -5-amino-pentanoic acid;  6- (C-α-D-galactopyranosyl) -5-amino-pentanoic acid; 10 137.  6- (C- (3-D-galactopyranosyl) -5-phenylaminopentanoic acid;  6- (C-α-D-galactopyranosyl) -5-phenylaminopentanoic acid; 139.  1- (C- (3-D-galactopyranosyl) -pentane-2,6-diol;  1- (C-α-D-galactopyranosyl) -pentane-2,6-diol; 141.  1- (C- (3-D-fucofuranosyl) propan-2-one; 142.  1- (C-α-D-fucofuranosyl) propan-2-one; 143.  1- (C- (3-L-fucofuranosyl) propan-2-one;  1- (C-α-L-fucofuranosyl) propan-2-one; 145.  3 '- (acetamido-C- (3-D-glucopyranosyl) propan-2'-one;  3 '- (acetamido-C-α-D-glucopyranosyl) propan-2'-one; 20 147.  1 - (acetamido-C- (3-D-glucopyranosyl) -2-hydroxylpropane; 148.  1- (acetamido-C-13-D-glucopyranosyl) -2-amino-propane; 149.  1- (acetamido-C-D-glucopyranosyl) -2-phenylamino propane; 150.  1- (acetamido-C-α-D-glucopyranosyl) -2-phenylamino propane; 151.  3-methyl-4- (acetamido-C-β-D-glucopyranosyl) butyric acid ethyl ester; 152.  3-methyl-4- (acetamido-C-α-D-glucopyranosyl) -butyric acid ethyl ester; 153.  6- (acetamido-C- (3-D-glucopyranosyl) -5-keto hexanoic acid;  6- (acetamido-C-α-D-glucopyranosyl) -5-keto hexanoic acid; 155.  6- (acetamido-C- (3-D-glucopyranosyl) -5-hydroxy-hexanoic acid;  6- (acetamido-C-α-D-glucopyranosyl) -5-hydroxy-hexanoic acid; 157.  6- (acetamido-C-D-glucopyranosyl) -5-aminohexanoic acid; 158.  6- (acetamido-C-α-D-glucopyranosyl) -5-aminohexanoic acid; 159.  6- (acetamido-C-13-D-glucopyranosyl) 5-phenylamino hexanoic acid; 5,160.  6- (acetamido-C-α-D-glucopyranosyl) 5-phenylamino hexanoic acid; 161.  1- (acetamido-C- (3-D-glucopyranosyl) hexane-2,6-diol;  1- (acetamido-C-α-D-glucopyranosyl) hexane-2,6-diol; 163.  6- (acetamido-C- (3-D-glucopyranosyl) -5-keto-pentanoic acid;  6- (acetamido-C-α-D-glucopyranosyl) -5-keto-pentanoic acid; 10,165.  6- (acetamido-C- (3-D-glucopyranosyl) -5-hydroxy-pentanoic acid;  6- (acetamido-C-α-D-glucopyranosyl) -5-hydroxypentanoic acid; 167.  6- (acetamido-C- (3-D-glucopyranosyl) -5-aminopentanoic acid;  6- (acetamido-C-α-D-glucopyranosyl) -5-aminopentanoic acid; 169.  6- (acetamido-C- (3-D-glucopyranosyl) -5-phenylaminopentanoic acid; 170.  6- (acetamido-C-α-D-glucopyranosyl) -5-phenylaminopentanoic acid; 171.  1- (acetamido-C-β-D-glucopyranosyl) -pentane-2,5-diol; 172.  1 - (acetamido-C-α-D-glucopyrano-syl) -pentane-2,5-diol.  By way of nonlimiting illustration of a C-glycoside derivative which is more particularly suitable for the invention, mention may be made especially of the following derivatives: C- (3-D-xylopyranoside-n-propan-2-one, CaD-xylopyranoside n-propan-2-one, - CPD-xylopyranoside-2-hydroxy-propane, - CaD-xylopyranoside-2-hydroxy-propane, 1- (C- (3-D-fucopyranoside) -propane -2-one, 1- (CaD-fucopyranoside) -propan-2-one, 1- (C- (3-L-fucopyranoside) -propan-2-one, 1- (CaL-fucopyranoside) ) -propan-2-one, 1- (C- (3-D-fucopyranoside) -2-hydroxypropane, 1- (CaD-fucopyranoside) -2-hydroxypropane, 1- (C- (3-L-fucopyranoside) -2-hydroxypropane, 1- (CaL-fucopyranoside) -2-hydroxypropane, 1- (C- (3-D-Glucopyranosyl) -2- hydroxyl-propane, 1- (CaD-Glucopyranosyl) -2-hydroxyl-propane, 1- (C- (3-D-galactopyranosyl) -2-hydroxyl-propane, 1- (CaD-galactopyranosyl) -2 1 - (C-β-D-fucofuranosyl) -propan-2-one, 1- (CaD-fucofuranosyl) -hydroxyl-propane propan-2-one 1- (C- (3-L-fucofuranosyl) -propan-2-one, 1- (CaL-fucofuranosyl) -propan-2-one, C- (3-D-maltopyranoside) n-propan-2-one, CaD-maltopyranoside-n-propan-2-one, C-13-D-maltopyranoside-2-hydroxy-propane, CaD-maltopyranoside-2-hydroxy-propane, their isomers and their Mixtures.  According to one embodiment, CPD-xylopyranoside-2-hydroxy-propane or CaD-xylopyranoside-2-hydroxy-propane, and better still C- (3-D-xylopyranoside-2-hydroxypropane, can be advantageously used. used for the preparation of a composition according to the invention.  According to one embodiment, it is possible to use C- (3-D-xylopyranoside-2-hydroxy-propane in the form of a solution containing 30% by weight of active ingredients in a mixture of water / 1,2 propane diol 60 / 40, such as that sold under the name MEXORYL SBB by the company CHIMEX.  Of course, according to the invention, a C-glycoside derivative corresponding to formula (I) may be used alone or as a mixture with other C-glycoside derivatives and in all proportions.  A C-glycoside derivative which is suitable for the invention may in particular be obtained by the synthesis method described in WO 02/051828.  The amount of C-glycoside derivative to be used in a composition according to the invention depends on the desired cosmetic or therapeutic effect, and can therefore vary to a large extent.  Those skilled in the art can easily, on the basis of their general knowledge, determine the appropriate amounts.  A composition according to the invention may comprise a C-glycoside derivative in a proportion of about 0.0001% to about 25% by weight relative to the total weight of the composition, and in particular of about 0.001% to about 10%. by weight, and more particularly from about 0.05 to 5% by weight of C-glycoside derivative active material relative to the total weight of the composition.  In general, this amount is adjusted to provide the desired effect in terms of complexion radiance.  A composition according to the invention comprises a physiologically acceptable medium.  This physiologically acceptable medium may comprise at least one aqueous phase mixed or not with one or more organic solvents such as a C1-C8 alcohol, especially ethanol, isopropanol, tert-butanol, n-butanol. polyols such as glycerine, propylene glycol, butylene glycol and polyol ethers.  A composition according to the invention may be anhydrous.  By anhydrous composition is meant any composition comprising less than 5% water relative to the total weight of the composition and more preferably less than 1% water.  A composition according to the invention may also comprise at least one fatty phase, which may comprise oils, gums, waxes usually used in the field of application in question.  Thus, according to one embodiment, a composition according to the invention may further comprise at least one fatty phase chosen from a fatty phase and / or a liquid fatty phase, solid at ambient temperature (20-25 ° C.) and atmospheric pressure.  A liquid fatty phase suitable for carrying out the invention may comprise a volatile oil, a non-volatile oil, and a mixture thereof.  A volatile or non-volatile oil may be a hydrocarbon oil, in particular of animal or vegetable origin, a synthetic oil, a silicone oil, a fluorinated oil or a mixture thereof.  A solid fatty phase that is suitable for carrying out the invention may be, for example, chosen from pasty fatty substances, gums, and mixtures thereof.  As oils or waxes that can be used in the invention, mention may be made of mineral oils (liquid petroleum jelly), vegetable oils (liquid fraction of shea butter, sunflower oil), animal oils (perhydrosqualene), synthetic oils (Purcellin oil), silicone oils or waxes (cyclomethicone) and fluorinated oils (perfluoropolyethers), bees, carnauba or paraffin waxes.  To these oils can be added fatty alcohols and fatty acids (stearic acid).  When a composition is an emulsion, the proportion of the fatty phase can range from 5% to 80% by weight, and preferably from 5% to 50% by weight relative to the total weight of the composition.  The oils, the waxes, the emulsifiers and the coemulsifiers used in the composition in emulsion form are chosen from those conventionally used in the cosmetics field.  An emulsifier and a coemulsifier may be present in a composition of the invention in a proportion ranging from 0.3% to 30% by weight, and in particular from 0.5% to 20% by weight relative to the total weight of the composition. .  An emulsion according to the invention may further contain lipid vesicles.  When a composition according to the invention is an oily solution or gel, the fatty phase may represent more than 90% of the total weight of the composition.  A composition according to the invention may also contain adjuvants customary in the field under consideration, such as surfactants, emulsifiers, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic additives, preservatives, antioxidants, solvents, perfumes, fillers, UVA and / or UVB filters (organic or inorganic, soluble or insoluble), fibers, chelating agents, odor absorbers, dyestuffs, and cosmetic or pharmaceutical active agents.  The amounts of these various adjuvants are those conventionally used in the cosmetics field, and may be, for example, from 0.01% to 25% of the total weight of the composition.  These adjuvants, depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into the lipid spherules.  Suitable surfactants that may be used include, for example, glycerol stearate, polysorbate 60 and the mixture of PEG-6 / PEG-32 / glycol stearate sold under the name Tefose® 63 by the company Gattefosse.  As hydrophilic gelling agents that can be used in the invention, mention may be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate / alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural gums and clays, and lipophilic gelling agents that may be mentioned are modified clays such as bentones, metal salts of fatty acids such as aluminum stearates and hydrophobic silica, polyethylene.  According to one embodiment, in a composition according to the invention, a C-glycoside may be associated with at least one additional dyestuff.  According to one embodiment, a coloring material may be chosen from fluorescent compounds, optical brighteners, pigments, pearlescent agents, and mixtures thereof.  When present, the additional coloring material (s) may represent preferably from 0.0005 to 12% by weight approximately of the total weight of the composition, and even more preferably from 0.005 to About 6% by weight of this weight.  Suitable dyestuffs according to the invention, especially in makeup compositions, include pigments, water-soluble or fat-soluble dyes, lacquers, and / or nacres.  As additional dyestuffs, there may be mentioned in particular monochromatic pigments, pearlescent agents, reflecting pigments that emit a color or do not emit, interferential pigments, fat-soluble dyes, water-soluble dyes, and mixtures thereof.  Fat-soluble dyes are, for example, Sudan Red, DC Red 17, DC Green 6, [3-carotene, soybean oil, Sudan Brown, DC Yellow 11, DC Violet 2, Orange DC. 5, yellow quinoline.  The pigments may be white or colored, mineral and / or organic, coated or uncoated.  Examples of inorganic pigments are titanium dioxide, optionally surface-treated, zirconium or cerium oxides, as well as iron or chromium oxides, manganese violet, ultramarine blue, chromium hydrate and ferric blue.  Among the organic pigments, mention may be made of carbon black, D & C type pigments, and lacquers based on cochineal carmine, barium, strontium, calcium, aluminum.  The pearlescent pigments may be chosen from white pearlescent pigments such as mica coated with titanium, or bismuth oxychloride, colored pearlescent pigments such as titanium mica with iron oxides, titanium mica with in particular ferric blue or chromium oxide, titanium mica with an organic pigment of the aforementioned type as well as pearlescent pigments based on bismuth oxychloride.  The pigments may have undergone a surface treatment.  In particular, it is possible to use pigments derived from bivalent metal salts, Fe 2 O 3, TiO 2, ZnO, chromium green oxide, or manganese violet.  In particular, a coloring material may comprise pigments and / or nacres.  Some coloring materials may provide in addition to a colored effect, an additional dynamic effect in terms of makeup rendering in the image of goniochromatic or fluorescent dyes, or optical brighteners.  Thus, a coloring material may comprise at least one fluorescent compound.  "Fluorescent compound" means a substance which, under the effect of ultraviolet light and / or visible light, re-emits in the visible the portion of light which it has absorbed in the same color as that which it naturally reflects .  The naturally reflected color is thus enhanced by the re-emitted color and appears extremely bright.  Fluorescent compounds may or may not be soluble in the physiologically acceptable medium.  As examples of fluorescent dyes soluble in the physiologically acceptable medium that may be used, mention may be made of fluorescent dyes belonging to the derivatives of the following families: naphthalimides; cationic or non-cationic coumarins; xanthenodiquinolizines (especially sulforhodamines); azaxanthenes; naphtholactams; azlactones; oxazines; Thiazines; dioxazines; polycationic fluorescent dyes of the azo, azomethine or methine type, alone or in mixtures.  As regards the fluorescent compounds which are not soluble in the physiologically acceptable medium that can be used in the process according to the invention, mention may be made of inorganic compounds, for example those based on zinc oxide or zinc sulphide.  Among the non-soluble organic fluorescent compounds in the physiologically acceptable medium, mention may be made of pigments made from fluorescent dyes which are previously dissolved in a carrier resin in order to obtain a solid solution which is then ground into a powder of resin with fluorescent properties.  The preparation of such fluorescent pigments is described in US Pat. No. 2,854,144 and US Pat.  The insoluble fluorescent compounds may thus be chosen from polyamide and / or formaldehyde / benzoguanamine and / or melanin / formaldehyde / sulfonamide colored resins, among the colored aminotriazine / formaldehyde / sulfonamide co-condensates and / or from the flakes.

  metallized polyester and / or mixtures thereof. These fluorescent compounds may also be in the form of aqueous dispersions. As fluorescent compounds that are suitable for the invention, it is also possible to obtain the medium-sized pink-colored fluorescent aminotriazine / formaldehyde / fluorescent sulfonamide of particles of 3-4 microns sold under the trade name Fiesta Astral Pink FEX-1 and the aminotriazine co-condensate. fluoride-colored formaldehyde / sulfonamide in medium-sized blue of the 3-4.5 micron particles sold under the trade name Fiesta Cornet Blue FTX-60 by the company Swada or the benzoguanamine / formaldehyde resin coated with formaldehyde / urea resin and colored in yellow sold under the trade name FB-205 Yellow and the benzoguanamine / formaldehyde resin coated with formaldehyde / urea resin and colored red sold under the trade name FB-400 Orange Red by UK company SEUNG CHEMICAL, the polyamide resin colored orange sold under the trade name Flare 911 Orange 4 by the company St erling Industrial Colors. The fluorescent compounds may preferably be present in a composition according to the invention at a content ranging from 0.05 to 20%, preferably from 0.1 to 10% by weight, more preferably from 0.5 to 5%. by weight, relative to the total weight of the composition. According to one embodiment, a coloring material may comprise at least one optical brightener.

When the organic fluorescent compounds are white, they are also called optical brighteners. An optical brightener has the effect of intensifying the brightness and brightening the hues of the cosmetic compositions comprising them to the application on the skin. Among the optical brighteners, mention may be made especially of stilbene derivatives, in particular polystyrylstilbenes and triazinstilbenes, coumarin derivatives, in particular hydroxycoumarines and aminocoumarines, oxazole, benzoxazole, imidazole, triazole and pyrazoline derivatives, and derivatives thereof. pyrene and porphyrin derivatives and / or mixtures thereof. Of the optical brighteners, stilbene derivatives, coumarin derivatives, oxazole and benzoxazole derivatives, and imidazole derivatives are especially suitable. The optical brighteners that can be used in the present invention can also be in the form of copolymers, for example acrylates and / or methacrylates, grafted with optical brightening groups as described in Application FR99-10942. Optical brighteners are for example available under the trade names Tinopal SOP and Uvitex OB from CIBA GEIGY. The optical brighteners preferentially used are sodium 4,4'-bis [(4,6-dianilino-1,3,5-triazin-2-yl) amino] stilbene-2,2'disulphonate, 2,5 thiophene di-γ1 bis (5-tert-butyl-1,3-benzoxazole), di-4,4-di-styryl-4,4'-biphenyl-di-sodium sulfonate and / or mixtures thereof. A composition of the invention may be in any conceivable galenic form.

In particular, a composition according to the invention can be in a fluid form of liquid type, paste, direct or inverse emulsion, or gel, or fluid deposited on a support (patch, wipes ..).

A composition according to the invention may, in particular, be in solid form of the compact type, pulverulent or cast or stick form. It can thus have the form of an aqueous solution, alcoholic, hydroalcoholic; a dispersion of the lotion or serum type; a water-in-oil, oil-in-water or multiple emulsion; a suspension; microcapsules or microparticles; vesicular dispersions of ionic and / or nonionic type; an aqueous lotion, oily or in the form of serum, foam, solid preparation; an aerosol composition also comprising a propellant under pressure of a vaporizable composition. It may also be in the form of a protection, treatment or skin care product, for example to be applied to the face and / or the neck (for example, day cream, night cream, anti-aging composition, etc.). solids, lotion, gel or mousse for skin care, artificial tanning composition), or a cleaning composition (for example make-up removing cream, cleaning lotions); or a facial makeup composition such as a foundation, a concealer, a concealer, a tinted cream or a makeup base for the face or a foundation. The invention also relates to a skincare and / or make-up composition that can be used in the process according to the invention, comprising, in a physiologically acceptable medium, at least one C-glycoside derivative and at least one Makeup agent with an optical effect that illuminates the skin. In particular, this illuminating optical effect makeup agent is selected from soft focus fillers, fluorescent compounds, optical brighteners, and mixtures thereof. Soft focus fillers, fluorescent compounds, and optical brighteners are more suitable for care and / or make-up compositions of the skin. Such a composition may further advantageously comprise dyestuffs. By charge sort-focus, we mean a charge which in addition gives transparency to the complexion and a fuzzy effect.

Preferably, the soft-focus charges have an average particle size of less than or equal to 15 microns. These particles may be of any shape and particularly spherical or nonspherical. More preferably, these fillers are nonspherical. The fate-focus fillers may be chosen from silica and silicate powders, in particular alumina powders, polymethyl methacrylate (PMMA) powders, talc, silica / TiO2 or silica / zinc oxide composites, powders of polyethylene, starch powders, polyamide powders, styrene / acrylic copolymer powders, silicone elastomers, and mixtures thereof. In particular, mention may be made of talc with a mean size of less than or equal to 3 microns, for example talc with a mean size in number of 1.8 micron and especially that sold under the trade name Talc P3 by the company Nippon Talc. , the Nylori 12 powder, in particular that sold under the name Orgasol 2002 Extra D Nat Cos by the company Atochem, the silica particles treated on the surface with a mineral wax 1 to 2% (INCI name: hydrated silica (and) paraffin) such as those marketed by Degussa, amorphous silica microspheres, such as those sold under the name Sunsphere, for example reference H-53 by Asahi Glass, and silica micro-beads such as those sold under the name denomination SB-700 or SB-150 by the company Miyoshi, this list not being limiting. The fuzziness filler may be present in the blur cosmetic composition in a content ranging from 0.1 to 20% by weight and in particular ranging from 1% to 12% by weight relative to the total weight of the composition. , especially between 5 and 10%, for example of the order of 8%. Also incorporated in the compositions of the invention are other colorless (mattifying, glossing agents) or colored makeup or makeup agents or agents which increase the hold or render the products resistant to water and secretions. It may be in particular a skin care and / or makeup composition, in particular a makeup composition for the skin.

For the purposes of the present invention, the care and / or make-up composition may in particular be applied to the skin of the face and / or the neck, in particular of a dark skin, in particular of phototype IV to VI.

A composition according to the invention may be applied by any means allowing a uniform distribution and especially using a cotton, a rod, a brush, a gauze, a spatula or a spatula. a buffer, or by spraying, and can be removed by rinsing with water or with a mild detergent.

A composition according to the invention may further comprise one or more cosmetic (s) or therapeutic (s) active (s). The invention also relates to the cosmetic use of at least one C-glycoside derivative as an agent for improving the radiance of the complexion of the skin and particularly of a dark skin of phototype IV to VI.

In particular, the C-glycoside derivative or the composition according to the invention is intended to prevent and / or reduce the ashiness of the skin, to make the complexion brighter, transparent, uniform, homogeneous, and / or of natural appearance. . The invention will be better understood on reading the detailed description which follows, of non-limiting examples of implementation thereof. EXAMPLES The C-glycoside derivative used in the examples below is C- (3-D-xylopyranoside-2-hydroxypropane marketed under the name MEXORYL SBB by the company CHIMEX and is in the form of a solution containing 30% by weight of active ingredient (MA) in a water / 1,2 propane diol 60/40 mixture.

EXAMPLE 1 Foundation for dark skin compounds% by weight Polymethylcetyldimetylmethoxysiloxane oxyethylenated (Abil EM 0.8 90 from Goldschmidt) Polyglycerol isso-stearate (4 moles) (Isolan GI 34 from 0.6 Goldschmidt) Hexyl laurate 0.6 Oxygenated Polydimethylsiloxane (KF 6017 from Shin Etsu 4.5 silicones) Isoeicosane (Permethyl 102A) 2.0 Polydimethylsiloxane 2.0 Cyclohexadimetylsiloxane 8 Cyclopentadimethylsiloxane 11 Isododecane 13 Vitamin E 0.1 Modified Hectorite (Bentone38V from Elementis) 1.6 Oxide yellow iron (Kobo FA50DYF) 6.9 Mica brown iron bismuth oxychloride (Engelhard Chroma-Lite 6.8 brown) Allura red aluminum lacquer on alumina (40/60) (FD & C 0.6 Red 40 Al lake of Noveon) Hollow microspheres of polymethyl methacrylate (Covabead 4.0 LH85 from Wackherr) Butylene glycol -1.3 10 Sodium chloride 0.7 C-13-D-xylopyranoside-2-hydroxypropane in solution at 30% by weight in a water / propylene glycol mixture 60 / 40 (Mexoryl SBB) preservative Qs water Qsp 100 * expressed in% of active ingredient Example 2 Cream Facial dark skin Compound% wt Phase A MIXTURE MONO / DISTEARATE OF 2 GLYCERYLE / STEARATE OF POLYETHYLENE GLYCOL (100 OE ARLACEL 165 from Uniqema ) FATTY ACIDS (STEARIC ACID 1 MAJORITY) OF VEGETABLE ORIGIN Trethanolamine 0.3 C12-15 alcohol benzoate 4 Vaseline oil 1 Polymethylene wax (Cirebelle 303 2 Sasol) Jojoba wax 2 4-METHOXYCINNAMATE 2-ETHYL 3 HEXYL (Parsol MCX) Cyclohexasiloxane 5 Isohexadecane 2 Vit E 0.1 Preservative qs Phase B COPOLYMER ACID 0.25 ACRYLIC / STEARYLE METHACRYLATE POLYMERIZED IN ETHYL ACETATE / CYCLOHEXANE MIXTURE: 2903006 28 (PEMULEN TR 1) 0.25 Trethanolamine Glycerol 5 propylene glycol C- (3-D-xylopyranoside-2-hydroxy-propane 5 * in solution at 30% by weight in a water / propylene glycol 60/40 mixture (Mexoryl SBB) preservative qs sequestering qs ACID B-B ' CAMPHOSULPHONIC [1-4 0.9 DIVINYLBENZENE] IN AQUEOUS SOLUTION ( Mexoryl SX) Trethanolamine 0.2 water Qsp 100 Phase C Perfume qs * expressed in% of active ingredient

Claims (24)

  1. Cosmetic and / or makeup care method intended to improve the radiance of the complexion of a dark skin, comprising the application to said skin of a composition comprising in a physiologically acceptable medium at least one C-glycoside derivative.   2. Method according to the preceding claim, wherein the dark skin is of phototype IV to VI of the FITZPATRICK classification.   3. Method according to claim 1 or 2, wherein said composition 10 provides after application to the skin, a negative variation of coxellography index Ai. less than or equal to -0.4, preferably less than or equal to -0.5, more preferably less than or equal to -1, for a skin having, before the application of said composition, a coxellography index ic0 greater than or equal to 5.   4. A process according to claim 2 or 3 wherein the C-glycoside derivative has the following general formula (I):   In which: R represents: a linear, saturated C1 to C20, in particular C1 to C10, unsaturated C 2 to C 20, in particular C 2 to C 10, alkyl radical, or an alkyl radical; branched or cyclic, saturated or unsaturated, C3-C20, in particular C3-C10; a linear hydrofluoro- or perfluoroalkyl radical, linear saturated with C 1 to C 20, in particular C 1 to C 10, or unsaturated C 2 to C 20, in particular C 2 to C 10, or branched or cyclic, saturated or unsaturated, C 3 to C 20 especially C3-C10; the hydrocarbon chain constituting said radicals may, if necessary, be interrupted by 1, 2, 3 or more heteroatoms chosen from: oxygen, sulfur, nitrogen, and silicon, and optionally substituted with at least one radical chosen from: - OR4, - -SR4i - NR4R5, --COOR4, -CONHR4, - CN, a halogen atom, - a C1 to C6 hydrofluoro- or perfluoroalkyl radical, and / or a C3-C8 cycloalkyl radical, with R4 and R5 being able to represent, independently of one another, a hydrogen atom, or an alkyl, perfluoroalkyl or linear hydrofluoroalkyl radical, saturated with C 1 to C 30, especially C1 to C12, or unsaturated C2 to C30, especially C2 to C12, or branched or cyclic, saturated or unsaturated, C3 to C30, especially C3 to C12; or a C6 to C10 aryl radical, X represents a radical chosen from the groups: OCN R2 R, C H'C ~ 20 with R1, R2 and R3 representing, independently of one another, a hydrogen atom; , or a radical R, with R as defined above, and R '1 representing a hydrogen atom R, a group OH or a radical R as defined above, RI may also denote a C6 aryl radical at Clo, - S represents a monosaccharide or a polysaccharide comprising up to 20 sugar units, in particular up to 6 sugar units, in pyranose and / or furanose form and 5 in series L and / or D, said mono- or poly -saccharide which may be substituted with a necessarily free hydroxyl group, and optionally one or more optionally protected amine function (s), and the S-CH 2 -X bond represents a C-anomeric bond, which can be a or 13, as well as their cosmetically acceptable salts, their solvates such s that hydrates and their isomers. 5. Method according to the preceding claim, wherein S represents a monosaccharide selected from D-glucose, D-xylose, L-fucose, D-galactose, D-maltose and especially D-xylose.   6. Process according to claim 4 or 5, in which X represents a group chosen from CO-, -CH (OH) -, -CH (NH 2) -, and preferentially a group -CH (OH) -.   7. Process according to any one of claims 4 to 6, wherein R denotes a linear radical C1-C4, in particular C1-C3, optionally substituted with OH, -COOH or ùCOOR "2, R" 2 being an alkyl radical. saturated C1-C4, especially ethyl.   8. Process according to any one of the preceding claims, in which the C-glycoside derivative is chosen from: C-13 -D-xylopyranoside-n-propan-2-one, - CaD-xylopyranoside-n-propane- 2-one, - C-13-D-xylopyranoside-2-hydroxy-propane, - CaD-xylopyranoside-2-hydroxy-propane, 1- (C- (3-D-fucopyranoside) -propane-2- one, 1- (CaD-fucopyranoside) -propan-2-one, 1- (C- (3-L-fucopyranoside) -propan-2-one, 1- (CaL-fucopyranoside) -propane-2 -one, 1- (C-13-D-fucopyranoside) -2-hydroxy-propane, 1- (CaD-fucopyranoside) -2-hydroxypropane, 1- (CPL-fucopyranoside) -2- hydroxy-propane, 1- (CaL-fucopyranoside) -2-hydroxy-propane, 1- (C- [3-D-Glucopyranosyl) -2-hydroxylpropane, 1- (CaD-Glucopyranosyl) -2 2-hydroxypropane, 1- (C- (3-D-galactopyranosyl) -2-hydroxylpropane, 1- (CaD-galactopyranosyl) -2-hydroxylpropane - 1- (C-) -D-fucofuranosyl) -propan-2-one, 1- (CaD-fucofuranosyl) -propan-2-one - 1- (C-F3-L-fucofuranosyl) propan-2-one, 1- (CaL-fucofuranosyl) -propan-2-one, C- (1D-maltopyranoside-n-propan-2-one, CaD-maltopyranoside-n-propan-2-one C-β-D-maltopyranoside-2-hydroxy-propane, CaD-maltopyranoside-2-hydroxy-propane, their isomers and their mixtures.   9. A process according to any one of the preceding claims wherein the C-glycoside derivative is selected from C- (3-D-xylopyranoside-2-hydroxy-propane and CaD-xylopyranoside-2-hydroxy-propane, and is more particularly C- (3-D-xylopyranoside-2-hydroxypropane.   10. Process according to any one of the preceding claims, in which the C-glycoside derivative is present in the composition in an amount ranging from 0.0001% to 25% by weight of active material relative to the total weight of the composition, and in particular from about 0.001% to about 10% by weight, and more preferably from 0.05 to 5% by weight based on the total weight of the composition. 25   11. The process as claimed in any one of the preceding claims, in which the C-glycoside derivative is associated with at least one additional dyestuff.   12. Method according to the preceding claim, wherein the coloring material is selected from a fluorescent compound, an optical brightener, pigments, pearlescent agents and mixtures thereof. 30   The process of any of the preceding claims, wherein said composition comprises at least one aqueous phase. 5 10 2903006 33   14. The method according to any one of the preceding claims, wherein said composition comprises at least one fatty phase.   15. Method according to the preceding claim, wherein said fatty phase contains at least one fatty phase which is liquid at room temperature and at atmospheric pressure and / or at least one solid fatty phase at ambient temperature and at atmospheric pressure.   16. A method according to any one of the preceding claims, wherein said composition is in a fluid form of liquid type, paste, direct or inverse emulsion, or gel, or fluid deposited on a support. 10   17. Method according to any one of claims 1 to 15, wherein said composition is in a solid form including compact, pulverulent or cast or stick form.   18. A method according to any one of the preceding claims, wherein said composition is in the form of a protection, treatment or skin care product to be applied to the face and / or the neck, a foundation, a concealer, a concealer, a tinted cream or a makeup base for the face and a foundation.   19. Skincare and / or make-up composition that can be used in the process according to any one of the preceding claims, comprising in a physiologically acceptable medium, at least one C-glycoside derivative and at least one chosen agent. among a soft focus charge, fluorescent compounds, optical brighteners, and mixtures thereof.   20. The composition of claim 19, wherein the C-glycoside derivative is as defined in any one of claims 4 to 9.   21. Cosmetic use of at least one C-glycoside derivative as an agent for improving the radiance of the complexion of a dark skin.   22. Use according to the preceding claim, wherein the dark skin is of phototype IV to VI of the classification of FITZPATRICK.   23. Use according to claim 21 or 22, wherein the C-glycoside derivative is as defined in any one of claims 4 to 9. 2903006 34   24. Use according to any one of claims 21 to 23, to prevent and / or reduce the ash appearance of the skin, make the complexion brighter, transparent, uniform, homogeneous and / or natural appearance.